Spread of clonal linezolid-resistant Staphylococcus epidermidis in an intensive care unit associated with linezolid exposure. 2020

Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
Department of Infectious diseases, Service de maladies infectieuses, university hospital of Besancon, 3 bd Alexandre Fleming, 25030, Besancon, France. kbouiller@chu-besancon.fr.

The aim of the study was to determine factors associated with spread of linezolid (LNZ)-resistant Staphylococcus epidermidis isolates in a surgical intensive care unit (ICU). A case-control study was conducted in one French adult surgical ICU. From January 2012 to December 2016, patients with at least a single positive LNZ-resistant S. epidermidis blood culture were matched to control with LNZ-susceptible S. epidermidis blood culture in a 1:4 manner. Cases were compared to controls regarding baseline clinical characteristics and LNZ exposure before positive blood culture. Bacterial isolates were genotyped by using pulsed-field gel electrophoresis (PFGE) and MLST. We identified 13 LNZ-resistant S. epidermidis isolates, 1 in 2012, 3 in 2014, 6 in 2015, and 3 in 2016. LNZ use increased steadily from 8 DDDs/100 patient days in 2010 to 19 in 2013 and further decrease by more of 50% in 2015 and 2016. The only independent risk factors associated to LNZ-resistant S. epidermidis isolation were length of stay in ICU before infection (OR 1.45; 95% CI 1.07-1.98), prior exposure to LNZ (OR 109; 95% CI 3.9-3034), and Charlson comorbidities score (OR 3.19; 95% CI 1.11-9.14). PFGE typing showed that all LNZ-resistant isolates were clonal belonging to ST2 and that LNZ-susceptible isolates were highly diverse. We report herein that previous exposure to LNZ substantially increased the risk of occurrence of LNZ resistance in S. epidermidis even in the case of clonal spread of LNZ-resistant isolates. These findings highlight the need for reducing the use of LNZ to preserve its efficacy in the future.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069349 Linezolid An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. Linezolide,N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide,PNU-100766,U 100766,U-100766,Zyvox,100766, U,PNU 100766,PNU100766,U100766

Related Publications

Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
April 2009, Diagnostic microbiology and infectious disease,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
April 2008, The Journal of antimicrobial chemotherapy,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
October 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
June 2021, Antimicrobial resistance and infection control,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
May 2009, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
April 2011, International journal of medical microbiology : IJMM,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
November 2012, International journal of antimicrobial agents,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
April 2012, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
June 2010, JAMA,
Kevin Bouiller, and Dejan Ilic, and Paul Henry Wicky, and Pascal Cholley, and Catherine Chirouze, and Xavier Bertrand
January 1983, Scandinavian journal of infectious diseases. Supplementum,
Copied contents to your clipboard!